CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 2,590 enrolled
Drug / intervention
Anti-androgen +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01368588
NCT01368588Phase 3Active

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Radiation Therapy Oncology Group·interventional·Posted Jun 8, 2011·Updated May 8, 2026

In Brief

A Phase 3 clinical trial evaluating three-dimensional conformal radiotherapy, intensity modulated radiotherapy, and 3 other interventions for Prostate Cancer. Active but no longer recruiting, targeting 2,590 participants across 478 sites in 6 countries.

Detailed Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada, Hong Kong, Israel, Singapore, Switzerland, United States

Timeline

Phase 3Active
2011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
First PostedJun 8, 2011
Enrollment StartJul 1, 2011
Primary CompletionApr 17, 2025
Study CompletionJul 1, 2031
TodayJul 2, 2026
Enrollment to primary: 13.8 yearsPosted 15.1 years ago

Interventions

three-dimensional conformal radiotherapyradiation

Daily fractions

intensity modulated radiotherapyradiation

Daily fractions

Brachytherapyradiation

Implant

Anti-androgendrug

Tablet

luteinizing hormone-releasing hormone (LHRH) agonist or antagonistdrug

Injection